Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(18):1315; doi:10.1093/jnci/dji333
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Japanese Translation
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

IN THIS ISSUE

The first 10% of the full text of this article appears below.

MGMT Promoter Methylation in Sporadic Colorectal Cancer

Sporadic colorectal cancers often arise from a region of cells characterized by a "field defect"—cells that appear normal but have an underlying molecular defect. The promoter of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) is frequently methylated in colorectal tumors. Shen et al. (p. 1330) used three different techniques to detect MGMT promoter methylation in 95 colorectal cancer patients and in 33 subjects with no evidence of cancer. They found that 46% of the tumors had MGMT promoter methylation. Patients whose tumors had MGMT promoter methylation also had substantial MGMT promoter methylation in apparently normal . . . [Full Text of this Article]

{beta}-Carotene and the Risk of Tobacco-Related Cancers

Anti–Helicobacter pylori Therapy for Gastric Lymphoma

Second Cancers Among Testicular Cancer Patients

Hormone Therapy and Mammographic Density

Mapping of a Susceptibility Locus in Malignant Melanoma


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?